SCHEMBL4425668

SCHEMBL4425668

N#C/C(=C\C=C\c1ccc([N+](=O)[O-])cc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAOB P27338 2/20 0.47
BCHE P06276 1/20 0.47
APP P05067 1/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.46
POLB P06746 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 1/20 0.46
ALPG P10696 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP1B1 Q16678 1/20 0.44
MAPT P10636 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29289233 0.85 PKM (0.67) PKML3MBTL1KDM4EALDH1A1MEN1
SCHEMBL29289228 0.85 PKM (0.67) PKML3MBTL1KDM4EALDH1A1MEN1
SCHEMBL4419297 0.78 KDM4E (0.72) PKML3MBTL1MAOBAPPKDM4E
SCHEMBL11450459 0.76 APP (0.61) MAOBBCHEAPPKDM4EALDH1A1
SCHEMBL11450460 0.76 APP (0.61) MAOBBCHEAPPKDM4EALDH1A1
SCHEMBL29289251 0.74 ALDH1A1 (0.60) PKML3MBTL1MAOBKDM4EALDH1A1
SCHEMBL29289250 0.74 ALDH1A1 (0.60) PKML3MBTL1MAOBKDM4EALDH1A1
SCHEMBL9364776 0.74 MAPT (0.56) MAOBBCHEAPPKDM4EALDH1A1
SCHEMBL9364774 0.74 MAPT (0.56) MAOBBCHEAPPKDM4EALDH1A1
SCHEMBL11757992 0.73 PKM (0.78) PKML3MBTL1KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197660-A1 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2007-08-23 US claimed
EP-1654220-A4 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2006-10-25 EP claimed
EP-1654220-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2006-05-10 EP claimed
US-20050085538-A1 Compounds for modulating cell proliferation HOSPITAL FOR SICK CHILDREN, THE (CA) 2005-04-21 US claimed
WO-2005012234-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2005-02-10 WO claimed
EP-1467967-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2004-10-20 EP claimed
WO-2003062190-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2003-07-31 WO claimed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US disclosed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US disclosed
US-20070197660-A1 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2007-08-23 US disclosed
US-20070197660-A1 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2007-08-23 US disclosed
US-20070197660-A1 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2007-08-23 US disclosed
US-20060241084-A1 Inhibition of vascular endothelial growth factor THE HOSPITAL FOR SICK CHILDREN (CA) 2006-10-26 US disclosed
EP-1551381-A2 STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR The Hospital for Sick Children (CA) 2005-07-13 EP disclosed
US-20050085538-A1 Compounds for modulating cell proliferation HOSPITAL FOR SICK CHILDREN, THE (CA) 2005-04-21 US disclosed
EP-1467967-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2004-10-20 EP disclosed
WO-2004032911-A2 STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR THE HOSPITAL FOR SICK CHILDREN (CA) 2004-04-22 WO disclosed
WO-2003062190-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241084-A1 Inhibition of vascular endothelial growth factor VEGFA, FLT4, FLT1 PKM 2600/4885L3MBTL1 4534/4885MAOB 495/4885
US-20050085538-A1 Compounds for modulating cell proliferation CCNO, CCNY, CCND3 PKM 4377/4885L3MBTL1 1668/4885MAOB 1268/4885
US-20070197660-A1 Compounds for modulating cell proliferation CCND3, CCNO, WNT3 PKM 4355/4885L3MBTL1 771/4885MAOB 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.